Ewing’s sarcoma recurrent – Diagnostics – Overview of Information and Clinical Research

When Ewing’s sarcoma returns after initial treatment, finding it early and understanding which tests are needed becomes crucial for planning the next steps in care and making informed decisions about treatment options.

Introduction: Who Needs Diagnostic Testing for Recurrent Ewing’s Sarcoma

Recurrent Ewing’s sarcoma means the cancer has come back after treatment. This happens when the disease either does not respond to the initial treatment or returns after a period during which it seemed to be gone. Anyone who has been treated for Ewing’s sarcoma in the past should be aware that the disease can recur, though not everyone will experience this^[2].

The most common place for Ewing’s sarcoma to come back is in the lungs. However, it can also return at the original location where the tumor first appeared, or it can spread to other parts of the body^[7]. Because of these possibilities, regular monitoring after completing treatment for Ewing’s sarcoma is essential. This ongoing surveillance helps catch any signs of recurrence as early as possible, which can make a significant difference in treatment planning.

People who should seek diagnostic testing include those who notice new symptoms after finishing their initial treatment. These symptoms might include pain or swelling in a new area, a lump (an abnormal growth or mass that can be felt under the skin), ongoing fever without an obvious cause, or trouble breathing. Anyone experiencing such changes should contact their doctor right away^[5].

Additionally, even without symptoms, patients who have completed treatment for Ewing’s sarcoma typically need regular follow-up visits with their healthcare team. During these visits, doctors will perform examinations and may order tests to check for any signs that the cancer has returned. The timing between the end of initial treatment and when recurrence happens matters greatly. Research shows that patients whose disease comes back more than two years after their first diagnosis tend to have better outcomes than those whose cancer returns sooner^[7].

⚠️ Important

If you have been treated for Ewing’s sarcoma and experience new pain, swelling, lumps, persistent fever, or breathing difficulties, contact your healthcare provider immediately. Early detection of recurrence can influence treatment decisions and outcomes. Do not wait for your next scheduled appointment if concerning symptoms appear.

Classic Diagnostic Methods for Detecting Recurrent Ewing’s Sarcoma

When doctors suspect that Ewing’s sarcoma may have returned, they use a combination of examinations and imaging tests to confirm whether the disease is present and to understand where it is located in the body. The diagnostic process for recurrent disease follows many of the same steps used when Ewing’s sarcoma is first discovered, but it takes into account the patient’s treatment history and the patterns in which this type of cancer typically recurs.

Physical Examination and Medical History

The diagnostic journey begins with a thorough physical examination and review of the patient’s health history. During this exam, the doctor checks for general signs of health and looks for anything unusual, such as lumps, areas of swelling, or signs of pain when certain body parts are touched. The physician will also ask detailed questions about any new symptoms, how long they have been present, and whether they are getting worse. Understanding the patient’s past treatments, including which chemotherapy drugs were used, whether radiation was given, and if surgery was performed, helps the doctor interpret test results and plan further investigations^[5].

Imaging Tests

Imaging tests create pictures of the inside of the body and are essential for finding areas where cancer may have returned. Several different types of imaging may be used, depending on what the doctor needs to see and where the cancer is suspected to be.

Magnetic resonance imaging, or MRI, uses magnets and radio waves to create detailed pictures of bones and soft tissues. This test is particularly useful for examining the area where the original tumor was located, as it can show whether cancer has come back in that spot or in nearby tissues. MRI scans do not use radiation and can provide very clear images of muscles, tendons, and other structures around bones^[5].

Computed tomography, or CT scan, uses X-rays taken from different angles and combines them with computer processing to create cross-sectional images of the body. CT scans are especially helpful for examining the chest, as they can detect small nodules or masses in the lungs where Ewing’s sarcoma often spreads. Because the lungs are the most common site of recurrence, chest CT scans are a standard part of follow-up care for patients who have been treated for this disease^[5].

X-rays are simpler imaging tests that create pictures of bones and some organs. While not as detailed as MRI or CT scans, X-rays can be useful for getting a quick look at specific areas of concern, particularly bones. They might be ordered if a patient has new bone pain or if a doctor wants to compare current bone structure to previous images.

Positron emission tomography, known as a PET scan, involves injecting a small amount of radioactive sugar into a vein. Cancer cells, which use more energy than normal cells, absorb more of this sugar and show up as bright spots on the scan. PET scans are often combined with CT scans in a single procedure called a PET-CT scan. This combination allows doctors to see both the metabolic activity of tissues and their exact location in the body, making it easier to identify areas of active cancer.

Laboratory Tests

While imaging tests show where tumors might be located, laboratory tests examine blood and other body fluids to assess overall health and look for signs of disease. Blood tests can check for abnormalities that might suggest cancer has returned, though they cannot diagnose recurrent Ewing’s sarcoma by themselves. These tests measure things like blood cell counts, organ function, and sometimes specific markers that can be elevated when cancer is present^[5].

Biopsy

A biopsy involves removing a small sample of tissue from a suspicious area so it can be examined under a microscope. This is the most definitive way to confirm that cancer has returned. During a biopsy, a doctor uses a needle or makes a small surgical incision to obtain tissue from a lump or mass. A specialist called a pathologist then looks at this tissue to determine whether it contains cancer cells and, if so, what type of cancer it is^[5].

For recurrent Ewing’s sarcoma, the biopsy is particularly important because it can confirm that the tumor is indeed Ewing’s sarcoma and not a different type of cancer. The tissue sample is also tested for specific genetic changes. Ewing’s sarcoma typically has a characteristic genetic feature where pieces of two different chromosomes, numbered 11 and 22, swap places. This creates a fusion of two genes, most commonly EWSR1 and FLI1. Finding this genetic signature helps confirm the diagnosis^[4].

Staging After Recurrence

Once recurrent Ewing’s sarcoma is confirmed, doctors need to determine the extent of the disease, a process called staging. This involves identifying all the places where cancer is present in the body. The staging process for recurrent disease uses the same imaging tests described earlier but focuses on creating a complete picture of where the cancer has spread. Doctors will examine the original tumor site, check the lungs carefully, and look at other bones and organs where the disease might have traveled^[5].

Understanding whether the recurrence is localized (limited to one area) or metastatic (spread to distant parts of the body) is crucial for treatment planning. Patients with only local recurrence, meaning the cancer has returned in or very near the original site, may have different treatment options compared to those whose disease has spread to distant organs like the lungs or other bones.

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or new combinations of existing treatments. For patients with recurrent Ewing’s sarcoma, participating in a clinical trial may offer access to promising therapies that are not yet widely available. However, to be eligible for most clinical trials, patients must meet specific criteria, and certain diagnostic tests are required to determine whether someone qualifies^[2].

Confirmation of Recurrent or Refractory Disease

The first requirement for most clinical trials is documented evidence that the Ewing’s sarcoma has either recurred after treatment or is refractory, meaning it did not respond adequately to initial therapy. This documentation typically includes pathology reports from a biopsy confirming the presence of Ewing’s sarcoma cells, along with imaging studies showing the location and extent of disease^[2].

Baseline Imaging and Tumor Measurements

Clinical trials often require baseline imaging studies to measure the size and location of tumors before any new treatment begins. These images serve as a reference point to determine whether the experimental treatment is working. Common baseline imaging includes CT scans of the chest, abdomen, and pelvis, as well as MRI scans of any areas where tumors are present. These measurements help researchers assess whether tumors shrink, stay the same size, or grow during the trial^[2].

Organ Function Tests

Many clinical trials have strict requirements regarding how well a patient’s organs are functioning. This is because experimental treatments can sometimes put stress on organs like the heart, liver, or kidneys. To ensure patients can safely tolerate the treatment being studied, trials require various tests of organ function before enrollment.

Heart function is typically assessed using an echocardiogram, which uses sound waves to create moving pictures of the heart, or sometimes a special type of scan that measures how well the heart pumps blood. These tests are particularly important because some chemotherapy drugs used to treat Ewing’s sarcoma can affect the heart.

Kidney function is evaluated through blood tests that measure substances like creatinine and calculate something called the glomerular filtration rate, which indicates how well the kidneys are filtering waste from the blood. Liver function is similarly assessed through blood tests that measure enzymes and other substances produced by the liver.

Blood tests are also used to check blood cell counts. Clinical trials typically require that patients have adequate numbers of white blood cells, red blood cells, and platelets before starting treatment. This ensures the body can fight infections, carry oxygen, and form blood clots when needed.

Performance Status Assessment

Clinical trials also evaluate how well patients can carry out daily activities, using what is called a performance status scale. This assessment helps determine whether someone is strong enough to tolerate the treatment being studied. Doctors rate patients on scales that range from being fully active and able to carry out all normal activities without restriction, to being completely bedbound and requiring constant care.

Genetic and Molecular Testing

Some clinical trials for recurrent Ewing’s sarcoma focus on treatments that target specific genetic or molecular features of the tumor. For these studies, additional testing of tumor tissue may be required. This can include looking for the specific gene fusion that caused the Ewing’s sarcoma, or testing for other genetic changes that might predict whether a particular targeted therapy will work. Fresh biopsies might be needed if older tumor samples are not available or if the trial protocol requires recently obtained tissue^[4].

⚠️ Important

Clinical trials for recurrent Ewing’s sarcoma are strongly encouraged when available, as the likelihood of cure with standard treatments remains low and much remains unknown about the best approaches. Enrollment in clinical trials should be discussed with your healthcare team to determine if you meet eligibility criteria and whether a trial might be appropriate for your situation.

Prior Treatment Documentation

Clinical trials need detailed records of what treatments patients have already received. This includes the names and doses of all chemotherapy drugs, the dates and locations where radiation therapy was given, and information about any surgeries performed. This documentation helps researchers understand whether previous treatments might affect how patients respond to the experimental therapy being tested. It also helps ensure that patients have not exceeded safe lifetime doses of certain drugs, such as those that can damage the heart^[2].

Time Since Last Treatment

Many clinical trials specify how much time must pass between previous treatments and enrollment in the study. For example, a trial might require that patients wait a certain number of weeks after finishing chemotherapy or radiation before beginning the experimental treatment. This waiting period allows the body to recover from previous therapy and helps ensure that any effects observed during the trial are due to the new treatment being studied and not lingering effects of prior treatments.

Prognosis and Survival Rate

Prognosis

The outlook for patients with recurrent Ewing’s sarcoma is considerably more challenging than for those with newly diagnosed disease. Several factors influence how the disease may progress after recurrence. The timing of when the cancer returns plays a critical role in determining outcomes. Patients whose disease recurs more than two years after their initial diagnosis generally have a better prognosis than those whose cancer returns sooner. In fact, research shows that patients with late recurrences can have five-year survival rates of around 35 percent, while those with earlier recurrences face more difficult odds^[7].

The location of recurrence also matters significantly. Patients who experience only local recurrence, meaning the cancer returns at or near the original tumor site, tend to have better outcomes than those with distant recurrences in organs like the lungs or other bones. When the disease comes back in just one location, particularly if aggressive surgery can completely remove it, patients have more favorable prospects. Studies indicate that patients with local recurrence who undergo radical surgery have better survival compared to those who do not receive such surgery^[7].

For patients whose cancer spreads to the lungs alone, radiation therapy to those areas may provide benefit. However, when recurrent disease appears in multiple locations throughout the body, the prognosis becomes more serious. Patients who have both local and distant recurrences face the greatest challenges, with five-year survival rates dropping to approximately 8 percent^[7].

Another important consideration is whether the cancer is truly recurrent, meaning it went away and then came back, versus refractory, meaning it never fully responded to initial treatment. Patients whose disease was refractory to first-line therapy generally have a worse prognosis than those who achieved an initial remission before experiencing recurrence^[7].

Survival Rate

The survival statistics for recurrent Ewing’s sarcoma paint a sobering picture. Research from English medical centers following 64 patients who experienced relapse found that the average survival time from the point of recurrence was only 14 months^[7]. This short timeframe underscores the aggressive nature of recurrent disease.

When looking at longer-term outcomes, a study from St. Jude Children’s Hospital that followed 71 patients with recurrent Ewing’s sarcoma found that the overall five-year relapse-free survival was 18 percent. This means that approximately one in five patients remained free of further disease progression five years after their recurrence was treated^[7].

Breaking these numbers down by type of recurrence provides more detailed insight. Patients with distant recurrence had a five-year relapse-free survival of 18 percent, while those with local recurrence fared slightly better at 22 percent. As mentioned earlier, patients with both local and distant recurrences had the poorest outcomes, with only 8 percent remaining relapse-free at five years^[7].

Overall survival rates for patients with recurrent or progressive Ewing’s sarcoma remain poor despite various treatment approaches including chemotherapy, surgery, radiation therapy, and even stem cell transplantation. The medical community recognizes that the likelihood of cure remains low and that significant gaps exist in understanding the best treatment approaches^[2].

It is important to note that these statistics represent averages from groups of patients and cannot predict exactly what will happen to any individual person. Every patient’s situation is unique, influenced by factors such as overall health, age, the specific characteristics of their tumor, and how well they respond to treatment. Some patients do much better than average statistics would suggest, while others face greater challenges. These numbers serve as general guides to help patients and families understand the seriousness of recurrent disease and the importance of considering all available treatment options, including participation in clinical trials when possible.

#1 Clinical Trials Search in Europe